Ingo Hartung, Executive Director, Head of Medicinal Chemistry and Drug Design at Merck Healthcare, shared a post on X:
“Highly significant selection of the first speaker in the opening plenary at AACR25: Kevan Shokat talking about the impressive progress in targeting KRas with small molecules. Decades of investing into fundamental science now generating first clinical impact. And much more to come.”
Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post by Ingo Hartung, adding:
“KRAS: from undruggable to this.”
